138 related articles for article (PubMed ID: 37063761)
1. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.
Barca-Hernando M; Lopez-Ruz S; Marin-Romero S; Garcia-Garcia V; Elias-Hernandez T; Otero-Candelera R; Carrier M; Jara-Palomares L
Res Pract Thromb Haemost; 2023 Feb; 7(2):100115. PubMed ID: 37063761
[TBL] [Abstract][Full Text] [Related]
2. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis.
van Hylckama Vlieg MAM; Nasserinejad K; Visser C; Bramer WM; Ashrani AA; Bosson JL; Crusan DJ; D'Alessio A; Fluharty ME; Ģībietis V; Hansson PO; Hara N; Jara-Palomares L; Kraaijpoel N; Mahé I; Marshall A; Ogino Y; Otero R; Versmissen J; Klok FA; Kruip MJHA; van der Rijt CCD; Geijteman ECT
EClinicalMedicine; 2023 Oct; 64():102194. PubMed ID: 37731937
[TBL] [Abstract][Full Text] [Related]
3. Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study.
Lapébie FX; Bura-Rivière A; Espitia O; Bongard V; Ciammaichella MM; Martínez JG; Sigüenza P; Giménez JC; Bertoletti L; Monreal M
J Thromb Haemost; 2023 Aug; 21(8):2189-2201. PubMed ID: 37068594
[TBL] [Abstract][Full Text] [Related]
4. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
[TBL] [Abstract][Full Text] [Related]
5. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
6. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
7. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
[TBL] [Abstract][Full Text] [Related]
8. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study.
Jara-Palomares L; Bikdeli B; Jiménez D; Muriel A; Demelo-Rodríguez P; Moustafa F; Villalobos A; López-Miguel P; López-Jiménez L; Otálora S; Peris ML; Amado C; Chopard R; Rivera-Cívico F; Monreal M;
EClinicalMedicine; 2024 Jul; 73():102659. PubMed ID: 38828131
[TBL] [Abstract][Full Text] [Related]
9. Venous Thromboembolism Recurrence in Latvian Population: Single University Hospital Data.
Ģībietis V; Kigitoviča D; Strautmane S; Meilande K; Kalējs VR; Zaičenko A; Maķe K; Lejnieks A; Skride A
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438542
[No Abstract] [Full Text] [Related]
10. Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism - Insights From the J'xactly Study.
Yamashita T; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Ikeda T; Mo M; Yamazaki T; Okumura Y; Hirayama A;
Circ Rep; 2022 Aug; 4(8):371-377. PubMed ID: 36032386
[No Abstract] [Full Text] [Related]
11. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
[TBL] [Abstract][Full Text] [Related]
12. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.
van der Hulle T; den Exter PL; van den Hoven P; van der Hoeven JJ; van der Meer FJ; Eikenboom J; Huisman MV; Klok FA
Chest; 2016 May; 149(5):1245-51. PubMed ID: 26836911
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with recurrent venous thromboembolism in patients with malignant disease.
Lin J; Proctor MC; Varma M; Greenfield LJ; Upchurch GR; Henke PK
J Vasc Surg; 2003 May; 37(5):976-83. PubMed ID: 12756342
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World.
Hara N; Lee T; Nozato T; Terui Matsuyama M; Okata S; Nagase M; Mitsui K; Nitta G; Watanabe K; Miyazaki R; Nagamine S; Kaneko M; Nakamura T; Nagata Y; Miyamoto T; Obayashi T; Ashikaga T
Circ J; 2022 May; 86(6):923-933. PubMed ID: 34645732
[TBL] [Abstract][Full Text] [Related]
15. The prediction role of D-dimer in recurrence of venous thromboembolism 1-year after anticoagulation discontinuing following idiopathic deep vein thrombosis.
Tamizifar B; Oghab P; Esfahani MA
J Res Med Sci; 2014 Jul; 19(7):586-91. PubMed ID: 25364355
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
17. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
[TBL] [Abstract][Full Text] [Related]
18. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
Douketis JD; Foster GA; Crowther MA; Prins MH; Ginsberg JS
Arch Intern Med; 2000 Dec 11-25; 160(22):3431-6. PubMed ID: 11112236
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study).
Otero R; Solier-López A; Sánchez-López V; Oto J; Arellano E; Marín S; Jara-Palomares L; Elías T; Asencio MI; Blasco-Esquivias I; Rodríguez de la Borbolla M; Sánchez-Díaz JM; Real-Domínguez M; García-Cabrera E; Rodríguez-Martorell FJ; Medina P
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
